What are the odds of catching an STI from a single unprotected sexual encounter with a new partner?
Evidence quality 4.5/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 4/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, activity-specific
1 in 1.5
65% lifetime chance
range 1 in 2.5 to 1 in 1.2
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Public perception of STI risk from a single encounter is shaped almost entirely by HIV awareness campaigns, which anchored the idea that unprotected sex is an acute mortal threat. Most adults substantially overestimate the per-act probability of HIV from heterosexual vaginal sex and substantially underestimate the per-act probability of HPV, which is the dominant contributor to composite STI acquisition risk. No rigorous population survey quantifies perceived per-encounter composite STI probability across pathogens, so this is marked as editorial intuition.
Rough estimate: Most adults perceive a 'significant' risk per encounter, heavily weighted toward HIV and heavily underweighting HPV
Source: editorial intuition, not polled
Actual
~1 in 11 per unprotected vaginal encounter with a random US adult partner (any STI)
Heterosexual US adults aged 18-59, random partner draw from general population
Show derivation
Scope is activity_specific_lifetime. The per-encounter composite probability of acquiring at least one new STI from a single act of unprotected vaginal sex with a random US adult partner is estimated at ~9% (1 in 11), calculated as 1 - product(1 - prevalence_i * transmissibility_i) across six major pathogens: HPV (~42.5% prevalence * ~20% per-act ≈ 8.5%), chlamydia (~1.8% * 4.5% ≈ 0.081%), gonorrhea (~0.3% * 20% ≈ 0.06%), HSV-2 (~12% * 0.15% ≈ 0.018%), HIV (~0.36% * 0.08% ≈ 0.00029%), syphilis (~0.05% * 5% ≈ 0.0025%). HPV dominates the composite, contributing ~94% of the total risk. The lifetime figure assumes 10 new partners over an adult sexual lifetime (roughly median for US adults per NHSLS/GSS data) with one unprotected vaginal encounter each: 1 - (1 - 0.09)^10 ≈ 0.61. Rounded up to ~0.65 to account for repeated encounters within partnerships and minor pathogen contributions not individually modeled (e.g., Mycoplasma genitalium, trichomoniasis). This is consistent with the CDC's estimate that ~80% of sexually active adults acquire HPV at some point, which alone implies a lifetime STI acquisition probability well above 0.5.
Caveats: These are per-act probabilities conditional on partner infection status weighted…
These are per-act probabilities conditional on partner infection status weighted by population prevalence. The calculation assumes a truly random partner draw from the US adult population, which does not reflect reality: sexual networks exhibit strong assortative mixing by geography, age, race, sexual orientation, and risk behavior. A person's actual risk depends heavily on who they select as partners and vice versa. All prevalence figures are US-centric; global prevalence varies enormously (HIV prevalence in sub-Saharan Africa is ~25x the US rate; HPV prevalence is high everywhere). Per-act transmissibility estimates carry wide confidence intervals and vary by viral load, co-infections, mucosal integrity, and host genetics. The composite treats pathogen acquisitions as independent events, which is approximately but not exactly true (STI co-infection raises susceptibility to other STIs, particularly HIV). This is a probability calculation based on published epidemiological data, not medical advice.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| Unprotected vaginal, heterosexual, US adult — any STI composite | 1 in 11 |
Per-encounter. HPV dominates (~8.5% contribution). Headline figure. |
| Same encounter with consistent condom use | 1 in 25 |
Condoms ~50-60% effective against HPV (skin-to-skin pathogen), ~80-90% against bacterial STIs and HIV. Composite roughly halved. |
| Receptive anal, MSM, major US metro — any STI | 1 in 4.0 |
HIV prevalence ~15% among MSM; gonorrhea/syphilis prevalence 5-10x general population. Per-act anal gonorrhea transmission ~30-50%. Composite far higher. |
| With PrEP — HIV-specific risk reduction | 1 in 10,000,000 |
PrEP reduces HIV acquisition risk by ~99% (Grant et al. 2010, iPrEx). Applies only to HIV; no effect on other STIs. |
| Serodiscordant couple, known HIV+ partner, no ART — receptive vaginal | 1 in 1,250 |
Patel 2014 per-act receptive vaginal: 8/10,000. With ART achieving viral suppression: effectively 0 (Cohen et al. 2016, HPTN 052). |
| HPV per-encounter (random US adult partner, unprotected vaginal) | 1 in 12 |
42.5% prevalence × ~20% per-encounter transmission. Dominant pathogen in composite. |
| Chlamydia per-encounter (random US adult partner, unprotected vaginal) | 1 in 1,235 |
~1.8% prevalence × ~4.5% per-act male-to-female transmission. |
| Gonorrhea per-encounter (random US adult partner, unprotected vaginal) | 1 in 1,667 |
~0.3% point prevalence × ~20% per-act male-to-female transmission. |
| HIV per-encounter (random US adult partner, unprotected vaginal) | 1 in 344,828 |
~0.36% prevalence × 0.08% per-act male-to-female. About 1 in 345,000. |
| HSV-2 per-encounter (random US adult partner, unprotected vaginal) | 1 in 5,556 |
~12% seroprevalence × ~0.15% per-act during asymptomatic shedding. About 1 in 5,500. |
| Syphilis per-encounter (random US adult partner, unprotected vaginal) | 1 in 40,000 |
~0.05% infectious-stage prevalence × ~5% per-act with infectious partner. About 1 in 40,000. |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Tick illness (forest)
What are the odds of catching a tick-borne illness from walking in the forest?
Adventure sports
What are the odds of a serious injury from regular participation in surfing, mountain biking, or rock climbing?
Drug-resistant infection
What is the risk of developing a serious antibiotic-resistant infection?
Family caregiver probability
How likely am I to become an unpaid family caregiver — and what is the mental-health toll?
Inheriting AUD risk
If a parent had alcohol use disorder, what are the odds you'll develop alcohol use disorder yourself?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The per-encounter probability of acquiring at least one new STI from a single act of unprotected vaginal sex with a random US adult partner is roughly 1 in 11, or about 9%. That number is almost entirely HPV: with a population prevalence of ~42.5% among US adults 18-59 and a per-new-partner transmission probability on the order of 20%, HPV contributes about 8.5 percentage points to the composite. Every other pathogen combined adds less than one percentage point. Over a lifetime with 10 new partners, the probability of acquiring at least one STI compounds to roughly 2 in 3, which is consistent with the CDC’s observation that around 80% of sexually active adults acquire HPV at some point.
The perception gap runs in two directions simultaneously. HIV, the pathogen that dominates public fear, has a per-encounter heterosexual vaginal transmission probability of about 1 in 345,000 from a random US adult partner (0.08% per-act transmissibility times 0.36% population prevalence). That is less likely per encounter than being struck by lightning in a given year. HPV, the pathogen that dominates actual acquisition risk, barely registers in public risk perception. The asymmetry is almost perfect: the highest-consequence, lowest-probability infection absorbs nearly all the fear budget, while the highest-probability infection is treated as a background inevitability. This is textbook dread-risk bias, where perceived severity and perceived probability become entangled.
The population-blinded per-encounter rate is a baseline, not a prediction. Actual risk is driven by partner selection. MSM face a composite per-encounter risk roughly 3x the heterosexual baseline, driven by HIV prevalence of ~15% among MSM (vs ~0.1% among heterosexuals) and higher gonorrhea/syphilis prevalence. Condom use roughly halves the composite, limited by their partial effectiveness against HPV and HSV-2 (skin-to-skin pathogens that transmit from areas not covered by the condom). Male circumcision reduces the composite by about 30% for insertive partners. PrEP eliminates nearly all HIV risk but has no effect on the other pathogens that dominate the composite. The arithmetic is clear on one point: for a heterosexual encounter with a partner drawn from the general US population, the question is overwhelmingly about HPV, not HIV.
Related tidbits
Serious vaccine adverse events: roughly 1-2 per million doses. Unprotected sex STI transmission per encounter: 1-30%. People decline the 1-in-a-million protection while accepting the 1-in-3 exposure.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] AIDS / Patel et al. (CDC) — Estimating per-act HIV transmission risk: a systematic review
Estimating per-act HIV transmission risk: a systematic review- Statistic
Per-act HIV transmission risk: receptive vaginal 8 per 10,000 (95% CI 6-11), insertive vaginal 4 per 10,000 (95% CI 1-14), receptive anal 138 per 10,000 (95% CI 102-186), insertive anal 11 per 10,000 (95% CI 4-28)- Excerpt
“"Sexual-exposure risks ranged from low for oral sex to 138 (CI 102-186) per 10,000 exposures for receptive anal intercourse. [...] Receptive vaginal intercourse: 8 (95% CI 6-11) per 10,000 exposures. Insertive vaginal intercourse: 4 (95% CI 1-14) per 10,000 exposures." ”
- Source data from
- 2014-06-19
- Accessed
- 2026-04-17 · archived copy
- Calculation
- Per-act receptive vaginal HIV risk = 8/10,000 = 0.08%. Combined with US adult HIV prevalence of ~0.36% (1.2M PLWH / 330M): per-encounter HIV risk from random partner = 0.0008 * 0.0036 = 0.0000029, or about 1 in 345,000. Even the higher receptive-anal figure of 1.38% * 0.36% prevalence = 0.005%, or ~1 in 20,000 per act with a random partner. HIV is a negligible contributor to the composite per-encounter risk in the general heterosexual US population.
- Independence
- CDC-authored systematic review of per-act HIV transmission studies; partially overlaps with Boily 2009 in included primary studies but uses a different analytic framework. The two meta-analyses converge on similar per-act estimates.
-
[2] US Centers for Disease Control and Prevention — Sexually Transmitted Infections Surveillance, 2024 (Provisional)
Sexually Transmitted Infections Surveillance, 2024 (Provisional)- Statistic
In 2024 (provisional), over 2.2 million cases of chlamydia, gonorrhea, and syphilis were reported: 1,515,985 chlamydia, 543,409 gonorrhea, 190,242 syphilis- Excerpt
“"There were still more than 2.2 million reported STIs in 2024. [...] Chlamydia cases declined for the second year in a row, down 8% since 2023. Gonorrhea cases declined for the third year in a row, down 10% since 2023. Primary and secondary syphilis cases declined for the second year in a row, down 22% since 2023." ”
- Source data from
- 2025-09-24
- Accessed
- 2026-04-24 · archived copy
- Calculation
- Reported cases understate true prevalence because most chlamydia and many gonorrhea infections are asymptomatic. Chlamydia point prevalence estimated at ~1.8% of adults (reported ~1.5M cases/year in 2024 provisional data, but screening captures only a fraction of infections; CDC estimates ~4M total infections/year against ~220M adults 18+). Gonorrhea point prevalence ~0.3% (reported ~543K cases/year, shorter duration of infection). Syphilis point prevalence ~0.05% (~190K all-stages cases but most are latent/non-infectious). These prevalence estimates feed into the composite calculation. The 2024 provisional data shows declines across all three bacterial STIs vs 2023.
- Independence
- National surveillance data from mandatory reporting; independent of the per-act transmission studies (Patel, Boily) and the prevalence surveys (McQuillan HPV, McQuillan HSV-2). Provides the incidence and case-count denominators for bacterial STI prevalence estimation.
-
[3] NCHS Data Brief No. 280 / McQuillan et al. — Prevalence of HPV in Adults Aged 18-69: United States, 2011-2014
Prevalence of HPV in Adults Aged 18-69: United States, 2011-2014- Statistic
During 2013-2014, any genital HPV prevalence among adults aged 18-59 was 42.5% overall (45.2% men, 39.9% women)- Excerpt
“"During 2013-2014, prevalence of any genital HPV for adults aged 18-59 was 42.5% (45.2% among men and 39.9% among women). Prevalence of high-risk genital HPV was 22.7%." ”
- Source data from
- 2017-04-01
- Accessed
- 2026-04-17 · archived copy
- Calculation
- HPV point prevalence of 42.5% among US adults 18-59 is the single largest contributor to per-encounter STI risk. Per-partnership HPV transmission probability is ~20% within the first few months (Burchell et al. 2006), implying a per-act rate on the order of ~20% for a new partner encounter (most transmission occurs rapidly after exposure). 0.425 * 0.20 = 0.085, or ~8.5% per encounter, which alone accounts for >94% of the composite STI risk.
- Independence
- NHANES-based population prevalence survey; independent of the per-act transmission studies and the bacterial STI surveillance data. Shares the McQuillan author with the HSV-2 data brief below but uses a different NHANES cycle and pathogen assay.
-
[4] NCHS Data Brief No. 304 / McQuillan et al. — Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14-49: United States, 2015-2016
Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14-49: United States, 2015-2016- Statistic
HSV-2 seroprevalence among persons aged 14-49 was 11.9% in 2015-2016, down from 18.0% in 1999-2000- Excerpt
“"During 2015-2016, prevalence of HSV-1 was 47.8% and HSV-2 was 11.9% among persons aged 14-49. Age-adjusted prevalence of HSV-2 decreased linearly over time by 5.9 percentage points, from 18.0% in 1999-2000 to 12.1% in 2015-2016." ”
- Source data from
- 2018-02-01
- Accessed
- 2026-04-17 · archived copy
- Calculation
- HSV-2 prevalence of ~12% combined with a per-act transmission probability of ~0.1-0.3% during asymptomatic shedding (Schiffer et al. 2014, J R Soc Interface; Wald and colleagues' longitudinal cohort data) gives a per-encounter risk from a random partner of ~0.12 * 0.0015 = 0.00018, or about 1 in 5,500. HSV-2 is a minor contributor to the single-encounter composite but compounds substantially over a lifetime of partnerships because shedding is intermittent and lifelong.
- Independence
- NHANES-based seroprevalence survey; shares the McQuillan lead author with the HPV data brief above but uses different NHANES cycles (2015-2016 vs 2011-2014) and a different serological assay. Provides the HSV-2 prevalence input to the composite calculation.
-
[5] The Lancet Infectious Diseases / Boily et al. — Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies
Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies- Statistic
Pooled per-act female-to-male HIV transmission in high-income countries: 0.04% (95% CI 0.01-0.14%); male-to-female: 0.08% (95% CI 0.06-0.11%); receptive anal: 1.7% (95% CI 0.3-8.9%)- Excerpt
“"Pooled female-to-male (0.04% per act [95% CI 0.01-0.14]) and male-to-female (0.08% per act [95% CI 0.06-0.11]) transmission estimates in high-income countries indicated a low per-act risk of infection in the absence of antiretrovirals. [...] The pooled receptive anal intercourse estimate was much higher (1.7% per act [95% CI 0.3-8.9])." ”
- Source data from
- 2009-02-01
- Accessed
- 2026-04-17 · archived copy
- Calculation
- Boily's meta-analysis corroborates Patel 2014 within overlapping confidence intervals. The high-income-country male-to-female rate of 0.08% is the figure used in the composite calculation for heterosexual vaginal sex. Multiplied by US adult HIV prevalence of 0.36%: 0.0008 * 0.0036 ≈ 2.9e-6 per encounter — confirming HIV's negligible contribution to the composite for population-blinded heterosexual encounters.
- Independence
- Lancet Infectious Diseases meta-analysis of observational cohort studies; partially overlaps with Patel 2014 in included studies but uses different pooling methodology. The convergence of the two meta-analyses raises confidence in the per-act estimates.
-
[6] US Centers for Disease Control and Prevention — Estimated HIV Incidence and Prevalence in the United States
Estimated HIV Incidence and Prevalence in the United States- Statistic
Estimated 1.2 million persons living with HIV in the United States at end of 2022; approximately 31,800 new infections in 2022- Excerpt
“"An estimated 1.2 million persons in the United States were living with diagnosed and undiagnosed HIV at the end of 2022. [...] Approximately 31,800 people acquired HIV in the United States in 2022." ”
- Source data from
- 2024-05-01
- Accessed
- 2026-04-17 · archived copy
- Calculation
- 1.2 million PLWH / 330 million US population = 0.36% adult prevalence. This is the population prevalence figure used to convert Patel/Boily per-act-given-infected-partner rates into per-encounter-with-random-partner rates. Note that prevalence is heavily concentrated among MSM (estimated ~15% prevalence among MSM vs ~0.1% among heterosexual adults), so the population-blinded 0.36% substantially overstates heterosexual encounter risk and understates MSM encounter risk.
- Independence
- National HIV Surveillance System data; independent of the per-act transmission meta-analyses and the NHANES prevalence surveys. Provides the population prevalence denominator used to convert conditional per-act rates into unconditional per-encounter-with-random-partner rates.







